Filing summary: Hywin Holdings Ltd. Form 20-F
Entity and period: The supplied filing is for Hywin Holdings Ltd. (Nasdaq: HYW), not Bitventures Ltd. It is an annual report for the fiscal year ended June 30, 2023, not a standalone 2022 Q4 report. Financial statements are prepared under U.S. GAAP; amounts below are RMB unless stated otherwise.
Business context
Hywin is a Cayman Islands holding company whose China operations are conducted through subsidiaries and contractual arrangements with variable interest entities (VIEs). Its services include wealth management, asset management, insurance brokerage and health management. Wealth management remains the largest business. The company does not own equity in the VIEs, although it consolidates them for accounting purposes.
Financial and operating metrics
| Metric | FY2023 | FY2022 | Change / context |
|---|---|---|---|
| Net revenue | RMB2,091.8m (US$301.3m) | RMB1,942.1m | Up 7.7% |
| Operating income | RMB197.4m | RMB326.7m | Down 39.6%; operating margin about 9.4%, versus 16.8% |
| Net income | RMB120.3m (US$17.3m) | RMB235.9m | Down 49.0%; net margin about 5.8%, versus 12.1% |
| Net income attributable to Hywin shareholders | RMB129.9m | RMB235.9m | FY2023 consolidated net income includes RMB9.6m loss attributable to noncontrolling interests |
| Operating cash flow | RMB525.3m | RMB238.8m | More than doubled; working-capital movements contributed |
| Investing cash flow | (RMB248.7m) | (RMB286.5m) | Primarily acquisitions and capital spending |
| Cash and cash equivalents | RMB868.9m | RMB525.1m | Excludes restricted cash |
| Restricted cash | RMB77.0m | RMB135.2m | Investor funds held under custody arrangements |
| Total assets / liabilities | RMB2,373.5m / RMB1,130.3m | RMB1,783.4m / RMB784.5m | Assets and liabilities increased, including from acquisitions and lease accounting |
| Borrowings | None reported at June 30, 2023 | RMB2.0m | FY2023 balance sheet includes operating lease liabilities of RMB184.1m |
Current assets were RMB1,469.8m against current liabilities of RMB1,009.2m, a current ratio of approximately 1.46. Accounts receivable declined to RMB415.1m from RMB564.4m; the filing reports no allowance for doubtful accounts at either year-end. Cash, cash equivalents and restricted cash together were RMB945.9m. Management said available cash and expected operating cash flow should cover anticipated needs for at least 12 months. About 89.4% of cash and cash equivalents was located in China. Gross margin is not separately presented.
Wealth management revenue was RMB1,949.4m, 93.2% of total revenue. Asset management revenue rose to RMB32.6m from RMB19.5m; AUM increased to RMB8.5bn from RMB4.5bn. Health management revenue reached RMB86.5m, following acquisitions, but the health segment recorded an operating loss of RMB111.1m, compared with RMB11.1m in FY2022. Total wealth-product transaction value declined to RMB72.6bn from RMB79.8bn. The repeat investment rate rose to 82.0% from 80.8%, while transaction value per relationship manager fell to RMB42.3m from RMB49.4m.
Material changes versus FY2022
- Revenue increased, but operating income and net income fell substantially as operating costs grew faster than revenue.
- Operating costs and expenses rose to RMB1,894.4m from RMB1,615.4m. FY2023 included RMB35.4m goodwill impairment and RMB2.2m intangible-asset impairment, primarily related to Grand Doctor, whose performance did not meet expectations.
- Health management costs rose to RMB74.5m from RMB4.3m, reflecting the acquired businesses and expanded services. Health management supplied 4.1% of FY2023 revenue but generated a significant segment loss.
- Insurance-product sales increased following the relaxation and removal of Hong Kong travel restrictions. Real-estate-related products declined to 28.0% of wealth-product transaction value from 37.9%.
- Cash from operations increased to RMB525.3m. The company attributed this partly to collections and other working-capital changes; investing outflows included RMB183.0m of acquisition payments.
Outlook, risks and unusual items
- No quantified revenue or earnings guidance is provided. Management anticipates continued health-management growth and stated that cash and expected operating cash flow should meet needs for at least 12 months.
- In September 2023, after the fiscal year-end, Hywin paid approximately RMB129.2m for land-use rights and construction in progress in Hainan for a planned health-management center. The project is at an early planning stage; the company estimates RMB500m–RMB1,000m of spending over the next 5–10 years, without a detailed budget.
- Key risks include enforceability of the VIE contracts and possible PRC intervention; evolving financial, overseas-listing, cybersecurity and data rules; exposure to real-estate-linked products; customer and provider concentration; and the early-stage health business. The top three customers represented 56% of FY2023 revenue, versus 37% in FY2022; the top five represented 66%, versus 52%.
- The company disclosed historical delays or shortfalls in paying certain VAT and income taxes and recorded tax payables. Income tax payable was RMB167.8m at June 30, 2023; value-added tax and other taxes payable were RMB245.4m. It also disclosed incomplete social-insurance and housing-fund contributions for some employees.
- Management concluded disclosure controls were ineffective at June 30, 2023. Material weaknesses included inadequate U.S. GAAP/SEC reporting resources and insufficient monitoring and review controls. Remediation was underway, but management said it could not conclude the weaknesses were fully remedied. The auditor gave an unqualified opinion on the financial statements but did not audit internal controls.
- The filing reports RMB1.0m of contingent liabilities related to litigation; management said no pending proceedings were expected to have a material impact. No dividend was declared or planned for the foreseeable future.
Important facts for investors to verify
- Confirm the filing identity and period: Hywin Holdings Ltd., fiscal year ended June 30, 2023; it does not report 2022 Q4 results.
- Review the audited statements and cash-flow detail, particularly the drivers of higher operating cash flow and the extent to which working-capital changes are repeatable.
- Assess customer concentration, receivable collectability and the absence of a reported receivables allowance, including the aging of balances.
- Track health-segment losses, acquisition performance and the funding, timetable and approvals for the Hainan project.
- Evaluate VIE enforceability, cash-transfer restrictions, tax and labor compliance exposures, and progress in remediating material control weaknesses.
- Reconcile share-count disclosures: the cover reports 47.75m ordinary shares excluding 8.25m shares issued to the depositary, while the financial statements report 56.0m issued and outstanding.